Q3 2021 Investor Relations Results

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (1 of 2) ADPT01 ADPT03 Oncology Code AAA603 Name 177 Lu-NeoB ADPT01 ADPT03 DKY709 DKY709 + spartalizumab HDM201 HDM201 + MBG453, venetoclax JBH492 JBH492 JDQ443 JDQ443 JEZ567 JEZ567 KAZ954 KAZ954 LXF821 LXF821 LXH254 LXH254 MAK683 MAK683 MBG453 MCM998 sabatolimab MCM998, LXG250 MIK665 MIK665 NIS793 NIS793, spartalizumab NIZ985 NZV930 PDR001 PHE885 PHE885 SQZ622 SQZ622 TNO155 TNO155 VAY736 VOB560 VOB560 VPM087 WNT974 ianalumab + ibrutinib gevokizumab WNT974+ spartalizumab WVT078 YTB323 WVT078 YTB323 Mechanism Radioligand therapy target GRPR BCL11A Novel immunomodulatory agent MDM2 inhibitor KRAS Inhibitor CD123 CAR-T EGFR CAR-T CRAF inhibitor EED inhibitor TIM3 antagonist BCMA CAR-T, CD19 CAR-T MCL1 inhibitor TGFB1 inhibitor Indication(s) Multiple solid tumors Colorectal cancer (combos) Sickle cell anemia Cancers Haematological malignancy Haematological malignancy KRAS G12C mutated solid tumors Acute myeloid leukaemia Solid tumors Glioblastoma multiforme NSCLC (combos) Cancers Low risk myelodysplastic syndrome Multiple myeloma Acute myeloid leukaemia (combo) Solid tumors NIZ985, spartalizumab NZV930, spartalizumab, NIR178 spartalizumab IL-15 agonist CD73 antagonist PD1 inhibitor BCMA cell therapy CD123xCD3 modulator SHP2 inhibitor BAFF-R inhibitor - IL-1 beta antagonist Porcupine inhibitor CD19 CAR-T Solid tumors Solid tumors Solid tumors (combo) Multiple Myeloma Acute myeloid leukaemia Solid tumors (single agent) Haematological malignancy Cancers Colorectal cancer, 1st line Solid tumors Multiple myeloma r/r DLBCL and r/r adult ALL 52 Investor Relations | Q3 2021 Results References Innovation: Clinical trials 34 lead indications Lead indication Solid tumors (combo) Solid tumors (combo) NOVARTIS | Reimagining Medicine

View entire presentation